Walleye Capital LLC Takes $428,000 Position in Arcus Biosciences, Inc. $RCUS

Walleye Capital LLC acquired a new stake in Arcus Biosciences, Inc. (NYSE:RCUS) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 54,582 shares of the company’s stock, valued at approximately $428,000. Walleye Capital LLC owned 0.05% of Arcus Biosciences at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of RCUS. E Fund Management Co. Ltd. bought a new position in shares of Arcus Biosciences in the first quarter valued at approximately $82,000. Lazard Asset Management LLC boosted its position in shares of Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after acquiring an additional 6,078 shares during the period. Knott David M Jr bought a new position in shares of Arcus Biosciences in the first quarter valued at approximately $94,000. Exchange Traded Concepts LLC boosted its position in shares of Arcus Biosciences by 40.5% in the first quarter. Exchange Traded Concepts LLC now owns 13,922 shares of the company’s stock valued at $109,000 after acquiring an additional 4,013 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of Arcus Biosciences by 21.3% in the first quarter. Oregon Public Employees Retirement Fund now owns 15,381 shares of the company’s stock valued at $121,000 after acquiring an additional 2,700 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Trading Up 2.0%

RCUS stock opened at $10.81 on Wednesday. The company has a market capitalization of $1.15 billion, a PE ratio of -3.41 and a beta of 0.83. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98. The company’s 50 day moving average price is $9.50 and its two-hundred day moving average price is $9.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.03. The firm had revenue of $160.00 million for the quarter, compared to the consensus estimate of $32.86 million. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The business’s revenue was up 310.3% compared to the same quarter last year. During the same period last year, the firm posted ($1.02) earnings per share. As a group, analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company lowered their target price on shares of Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Morgan Stanley lowered their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Arcus Biosciences in a research note on Wednesday, May 7th. The Goldman Sachs Group lowered their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen raised shares of Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 9th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.14.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.